What this Trial Is About

Atopic eczema is a chronic inflammatory skin condition mainly affecting children, marked by itching and flare-ups. This study evaluates the effectiveness of a dermocosmetic product compared to a placebo in managing atopic skin, focusing on reducing the number, timing, and severity of eczema recurrences. The study also looks at symptoms including dryness, itching, and sleep quality, while monitoring skin acceptability of the treatments. Participants are randomly assigned to receive either the study product, which is an anti-itching, anti-relapse, and repairing emollient treatment, or a placebo emollient. These products are applied under dermatological supervision, alongside the participants' ongoing topical corticosteroid treatments. The study is conducted as a multicenter, double-blind clinical trial. During the study, eczema severity is measured using the SCORAD score at baseline (Day -X), Day 0, and at 2, 4, and 6 months after starting treatment. Dermatologists examine participants' skin on these same days to assess skin acceptability and monitor symptoms like dryness, itching, and sleep disturbances. Quality of life, sleep quality, and safety are also evaluated throughout the trial, which includes children aged 3 months to 12 years.

Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.